Evidence map›Paper›PMID 32593418›Full record

ReviewHeart & lung : the journal of critical care

A review of cardiac manifestations and predictors of outcome in patients with COVID - 19.

Ajay Kumar Mishra, Kamal Kant Sahu, Anu Anna George, Amos Lal

Open access · bronzeAbstract readReview
In one paragraph

Review in Heart & lung : the journal of critical care. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Prognostic significance of CHADSJournal of cardiovascular and thoracic research · 2022
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Different SARS-CoV-2 haplotypes associate with geographic origin and case fatality rates of COVID-19 patients.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Ajay Kumar MishraResident, Department of Internal Medicine, St Vincent Hospital, 123 summer street, Worcester, MA, USA. Electronic address: Ajay.Mishra@stvincenthosptial.com.
Kamal Kant SahuResident, Department of Internal Medicine, St Vincent Hospital, 123 summer street, Worcester, MA, USA. Electronic address: Kamalkant.Sahu@stvincenthospital.com.
Anu Anna GeorgeResident, Department of Internal Medicine, St Vincent Hospital, 123 summer street, Worcester, MA, USA.
Amos LalFellow in Department of Pulmonology and Critical Care Medicine, Mayo Clinic, Rochester, USA. Electronic address: Lal.Amos@mayo.edu.
St Vincent Hospital · USMayo Clinic in Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease (COVID-19) pandemic has so far involved 184 countries and more than 2.79 million patients worldwide. Over the past three months, it has attributed to more than 196,000 deaths, with more than 50,000 deaths in the United States alone. Pulmonary manifestations are predominant and have been well identified. Cardiac involvement is also common. Acute cardiac injury, the most common cardiac manifestation of this disease can be seen in patients even without prior cardiac comorbidities. Established cardiovascular risk factors such as diabetes mellitus, hypertension, and coronary artery disease predispose to cardiac injury, the severity of illness and mortality. Non-ischemic myocardial injury secondary to cytokine storm is thought to be the predominant mechanism of acute cardiac injury associated with COVID-19. Multiple mechanisms and processes contribute to cardiac injury resulting in a poor outcome. Some of these are not clearly understood. Clinical and diagnostic details of cardiovascular involvement in these patients are mostly limited to biochemical markers. Multiple therapeutic agents have been tried with questionable efficacy and without clinical evidence. Interactions of comorbidities, cardiovascular drugs, the cardiac effect of therapeutic agents on the illness continue to be under investigation. With an increasing number of patients, newer promising therapies, and ongoing clinical trials, the exact mechanisms and extent to which these risk factors contribute to outcomes will be clearer in the future.

Indexed as

BiomarkersComorbidityCoronavirus InfectionsCOVID-19Heart DiseasesHumansPandemicsPneumonia, ViralRisk FactorsBiomarkersCardiac manifestationCOVID -19MechanismOutcomeRisk factors

Identifiers

PMID32593418
PMCPMC7196397
OpenAlexW3022039883

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.